Renal Denervation Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented by Technology (Ultrasound Ablation, Radiofrequency Ablation, Pharmacologic Ablation, and Microinfusion), By Product (Catheters, Single Electrode Catheter, Multi Electrode Catheter, RF Generator, and Others), By Therapeutic Area (Hypertension, Heart Failure, Diabetes, Renal Failure, and Others), By End User (Hospitals & Clinics, Ambulatory Care Centers, and Others), By Region and Competition
Global Renal Denervation Market is anticipated to witness a growth of steady CAGR in the forecast period, 2024-2028. It can be ascribed to increasing innovation of renal denervation system, increase in hypertension cases due to consuming alcohol, and unhealthy foods, growing usage of the endovascular catheter, radiofrequency ablation, and the continuous rise in the number of heart failure cases. However, increasing funding for R&D activities for treating renal abnormalities by various regulators and some state governments and the significant number of benefits of this method, along with the increasing efforts and initiatives being introduced by influential Market players, will propel the market in the forecast period. The occurrence of hypertension has increased from 17,307 per 100,000 in 1990 to 20,525 per 100,000 in 2015. The rising burden of chronic diseases like obesity among children and adults will power renal denervation market trends through the forecast period.
Rising incidence of hypertension among people
With the increasing modernization worldwide, people's lifestyles are majorly being changed. The day-to-day routines of people worldwide are increasingly becoming hectic. Hypertension is a significant and modifiable risk factor for cardiovascular disorders and diseases, chronic kidney disease, and death. The prevalence of hypertension has been observing a substantial rise over the past few years. Because more strict BP objectives are recommended by guidelines, obtaining these targets necessitates using multiple drugs, resulting in increased dosing complexity, expense, pill burden, and drug intolerance. Some significant reasons for an increase in the prevalence of hypertension are the increasing geriatric population, high sodium, and low potassium intake, rising cases of obesity, increasing alcohol consumption in low- and middle-income countries, physical inactivity, and the lack of a balanced diet. The rising number of geriatrics worldwide is one of the primary reasons for an increase in the risk of hypertension. According to the World Health Organization, 2021, around 1.28 billion people aged between 30 and 79 are globally affected by hypertension.
Advancement of Renal Denervation
The number of new capabilities introduced in the renal denervation approach is one of the major factors accelerating its adoption. Renal denervation systems that incorporate ultrasound technology can overcome the limitations of radiofrequency-based renal denervation systems. The high-frequency sound waves of the ultrasonic energy aid in ablating nerves without coming into close touch with the tissues. This aids in the prevention of renal artery damage. Due to this attribute, many patients worldwide prefer this technology. Moreover, integrating technology into these kinds of healthcare practices offers a considerable scale of enhancements in the outcomes of these techniques. The advancement of renal denervation will boost the market in the forecast period. Almost about 47% of adults in the United States have hypertension, have a systolic blood pressure greater than 130 mmHg or a diastolic blood pressure greater than 80 mmHg, or are taking medication for hypertension. Only about 1 in 4 adults (24%) with hypertension have their condition under control.
Market Segmentation
The Global Renal Denervation market is segmented based on technology, product, therapeutic area, end user, and by region. Based on technology, the market can be segmented into Ultrasound Ablation, Radiofrequency Ablation, Pharmacologic Ablation, and Microinfusion. Based on product, the market can be differentiated into Catheters, Single Electrode Catheter, Multi-Electrode Catheter, RF Generator, and Others. Based on therapeutic area, the market can be differentiated into Hypertension, Heart Failure, Diabetes, Renal Failure, and Others. Based on end users, the market can be segmented into Hospitals & Clinics, Ambulatory Care Centers, and Others. Regionally, Europe dominated the market among Asia Pacific, North America, Middle East & Africa, and South America. In terms of country, the United States region dominates the global renal denervation market. According to CDC, in 2021, more than 670,000 deaths in the United States had hypertension as a primary or contributing cause.
Market Players
Medtronic Plc., Boston Scientific Corporation, Abbott Laboratories, Inc., Terumo Corporation, Johnson & Johnson, Cordis Corporation, ReCor Medical, Inc. (Otsuka Holdings), Cardiosonic Ltd, Mercator MedSystems, Inc, Renal Dynamics Limited are some of the leading players operating in the Global Renal Denervation Market.
Report Scope:
In this report, Global Renal Denervation market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Company Profiles: Detailed analysis of the major companies present in Global Renal Denervation Market.
Available Customizations:
With the given market data, TechSci Research offers customizations according to a company’s specific needs. The following customization options are available for the report:
Company Information
Rising incidence of hypertension among people
With the increasing modernization worldwide, people's lifestyles are majorly being changed. The day-to-day routines of people worldwide are increasingly becoming hectic. Hypertension is a significant and modifiable risk factor for cardiovascular disorders and diseases, chronic kidney disease, and death. The prevalence of hypertension has been observing a substantial rise over the past few years. Because more strict BP objectives are recommended by guidelines, obtaining these targets necessitates using multiple drugs, resulting in increased dosing complexity, expense, pill burden, and drug intolerance. Some significant reasons for an increase in the prevalence of hypertension are the increasing geriatric population, high sodium, and low potassium intake, rising cases of obesity, increasing alcohol consumption in low- and middle-income countries, physical inactivity, and the lack of a balanced diet. The rising number of geriatrics worldwide is one of the primary reasons for an increase in the risk of hypertension. According to the World Health Organization, 2021, around 1.28 billion people aged between 30 and 79 are globally affected by hypertension.
Advancement of Renal Denervation
The number of new capabilities introduced in the renal denervation approach is one of the major factors accelerating its adoption. Renal denervation systems that incorporate ultrasound technology can overcome the limitations of radiofrequency-based renal denervation systems. The high-frequency sound waves of the ultrasonic energy aid in ablating nerves without coming into close touch with the tissues. This aids in the prevention of renal artery damage. Due to this attribute, many patients worldwide prefer this technology. Moreover, integrating technology into these kinds of healthcare practices offers a considerable scale of enhancements in the outcomes of these techniques. The advancement of renal denervation will boost the market in the forecast period. Almost about 47% of adults in the United States have hypertension, have a systolic blood pressure greater than 130 mmHg or a diastolic blood pressure greater than 80 mmHg, or are taking medication for hypertension. Only about 1 in 4 adults (24%) with hypertension have their condition under control.
Market Segmentation
The Global Renal Denervation market is segmented based on technology, product, therapeutic area, end user, and by region. Based on technology, the market can be segmented into Ultrasound Ablation, Radiofrequency Ablation, Pharmacologic Ablation, and Microinfusion. Based on product, the market can be differentiated into Catheters, Single Electrode Catheter, Multi-Electrode Catheter, RF Generator, and Others. Based on therapeutic area, the market can be differentiated into Hypertension, Heart Failure, Diabetes, Renal Failure, and Others. Based on end users, the market can be segmented into Hospitals & Clinics, Ambulatory Care Centers, and Others. Regionally, Europe dominated the market among Asia Pacific, North America, Middle East & Africa, and South America. In terms of country, the United States region dominates the global renal denervation market. According to CDC, in 2021, more than 670,000 deaths in the United States had hypertension as a primary or contributing cause.
Market Players
Medtronic Plc., Boston Scientific Corporation, Abbott Laboratories, Inc., Terumo Corporation, Johnson & Johnson, Cordis Corporation, ReCor Medical, Inc. (Otsuka Holdings), Cardiosonic Ltd, Mercator MedSystems, Inc, Renal Dynamics Limited are some of the leading players operating in the Global Renal Denervation Market.
Report Scope:
In this report, Global Renal Denervation market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
- Renal Denervation Market, By Technology:
- Ultrasound Ablation
- Radiofrequency Ablation
- Pharmacologic Ablation
- Microinfusion
- Renal Denervation Market, By Product:
- Catheters
- Single Electrode Catheter
- Multi-Electrode Catheter
- RF Generator
- Others
- Renal Denervation Market, By Therapeutic Area:
- Hypertension
- Heart Failure
- Diabetes
- Renal Failure
- Others
- Renal Denervation Market, By End User:
- Hospitals & Clinics
- Ambulatory Care Centers
- Others
- Renal Denervation Market, By Region:
- North America
- United States
- Mexico
- Canada
- Europe
- France
- Germany
- United Kingdom
- Italy
- Spain
- Asia Pacific
- China
- India
- South Korea
- Japan
- Australia
- South America
- Brazil
- Argentina
- Colombia
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
- Egypt
- Turkey
Company Profiles: Detailed analysis of the major companies present in Global Renal Denervation Market.
Available Customizations:
With the given market data, TechSci Research offers customizations according to a company’s specific needs. The following customization options are available for the report:
Company Information
- Detailed analysis and profiling of additional market players (up to five).
1. PRODUCT OVERVIEW
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. RESEARCH METHODOLOGY
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. EXECUTIVE SUMMARY
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. VOICE OF CUSTOMER
5. GLOBAL RENAL DENERVATION MARKET OUTLOOK
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Technology (Ultrasound Ablation, Radiofrequency Ablation, Pharmacologic Ablation, Microinfusion)
5.2.2. By Product (Catheters, Single Electrode Catheter, Multi Electrode Catheter, RF Generator, Others)
5.2.3. By Therapeutic Area (Hypertension, Heart Failure, Diabetes, Renal Failure, Others)
5.2.4. By End User (Hospitals & Clinics, Ambulatory Care Centers, Others)
5.2.5. By Region
5.2.6. By Company (2022)
5.3. Market Map
5.3.1. By Technology
5.3.2. By Product
5.3.3. By Therapeutic Area
5.3.4. By End User
5.3.5. By Region
6. NORTH AMERICA RENAL DENERVATION MARKET OUTLOOK
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Technology
6.2.2. By Product
6.2.3. By Therapeutic Area
6.2.4. By End User
6.2.5. By Country
6.3. North America: Country Analysis
6.3.1. United States Renal Denervation Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Technology
6.3.1.2.2. By Product
6.3.1.2.3. By Therapeutic Area
6.3.1.2.4. By End User
6.3.2. Mexico Renal Denervation Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Technology
6.3.2.2.2. By Product
6.3.2.2.3. By Therapeutic Area
6.3.2.2.4. By End User
6.3.3. Canada Renal Denervation Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Technology
6.3.3.2.2. By Product
6.3.3.2.3. By Therapeutic Area
6.3.3.2.4. By End User
7. EUROPE RENAL DENERVATION MARKET OUTLOOK
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Technology
7.2.2. By Product
7.2.3. By Therapeutic Area
7.2.4. By End User
7.2.5. By Country
7.3. Europe: Country Analysis
7.3.1. France Renal Denervation Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Technology
7.3.1.2.2. By Product
7.3.1.2.3. By Therapeutic Area
7.3.1.2.4. By End User
7.3.2. Germany Renal Denervation Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Technology
7.3.2.2.2. By Product
7.3.2.2.3. By Therapeutic Area
7.3.2.2.4. By End User
7.3.3. United Kingdom Renal Denervation Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Technology
7.3.3.2.2. By Product
7.3.3.2.3. By Therapeutic Area
7.3.3.2.4. By End User
7.3.4. Italy Renal Denervation Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Technology
7.3.4.2.2. By Product
7.3.4.2.3. By Therapeutic Area
7.3.4.2.4. By End User
7.3.5. Spain Renal Denervation Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Technology
7.3.5.2.2. By Product
7.3.5.2.3. By Therapeutic Area
7.3.5.2.4. By End User
8. ASIA-PACIFIC RENAL DENERVATION MARKET OUTLOOK
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Technology
8.2.2. By Product
8.2.3. By Therapeutic Area
8.2.4. By End User
8.2.5. By Country
8.3. Asia-Pacific: Country Analysis
8.3.1. China Renal Denervation Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Technology
8.3.1.2.2. By Product
8.3.1.2.3. By Therapeutic Area
8.3.1.2.4. By End User
8.3.2. India Renal Denervation Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Technology
8.3.2.2.2. By Product
8.3.2.2.3. By Therapeutic Area
8.3.2.2.4. By End User
8.3.3. Japan Renal Denervation Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Technology
8.3.3.2.2. By Product
8.3.3.2.3. By Therapeutic Area
8.3.3.2.4. By End User
8.3.4. South Korea Renal Denervation Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Technology
8.3.4.2.2. By Product
8.3.4.2.3. By Therapeutic Area
8.3.4.2.4. By End User
8.3.5. Australia Renal Denervation Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Technology
8.3.5.2.2. By Product
8.3.5.2.3. By Therapeutic Area
8.3.5.2.4. By End User
9. SOUTH AMERICA RENAL DENERVATION MARKET OUTLOOK
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Technology
9.2.2. By Product
9.2.3. By Therapeutic Area
9.2.4. By End User
9.2.5. By Country
9.3. South America: Country Analysis
9.3.1. Brazil Renal Denervation Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Technology
9.3.1.2.2. By Product
9.3.1.2.3. By Therapeutic Area
9.3.1.2.4. By End User
9.3.2. Argentina Renal Denervation Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Technology
9.3.2.2.2. By Product
9.3.2.2.3. By Therapeutic Area
9.3.2.2.4. By End User
9.3.3. Colombia Renal Denervation Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Technology
9.3.3.2.2. By Product
9.3.3.2.3. By Therapeutic Area
9.3.3.2.4. By End User
10. MIDDLE EAST AND AFRICA RENAL DENERVATION MARKET OUTLOOK
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Technology
10.2.2. By Product
10.2.3. By Therapeutic Area
10.2.4. By End User
10.2.5. By Country
10.3. MEA: Country Analysis
10.3.1. South Africa Renal Denervation Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Technology
10.3.1.2.2. By Product
10.3.1.2.3. By Therapeutic Area
10.3.1.2.4. By End User
10.3.2. Saudi Arabia Renal Denervation Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Technology
10.3.2.2.2. By Product
10.3.2.2.3. By Therapeutic Area
10.3.2.2.4. By End User
10.3.3. UAE Renal Denervation Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Technology
10.3.3.2.2. By Product
10.3.3.2.3. By Therapeutic Area
10.3.3.2.4. By End User
10.3.4. Egypt Renal Denervation Market Outlook
10.3.4.1. Market Size & Forecast
10.3.4.1.1. By Value
10.3.4.2. Market Share & Forecast
10.3.4.2.1. By Technology
10.3.4.2.2. By Product
10.3.4.2.3. By Therapeutic Area
10.3.4.2.4. By End User
10.3.5. Turkey Renal Denervation Market Outlook
10.3.5.1. Market Size & Forecast
10.3.5.1.1. By Value
10.3.5.2. Market Share & Forecast
10.3.5.2.1. By Technology
10.3.5.2.2. By Product
10.3.5.2.3. By Therapeutic Area
10.3.5.2.4. By End User
11. MARKET DYNAMICS
11.1. Drivers
11.2. Challenges
12. MARKET TRENDS & DEVELOPMENTS
12.1. Recent Developments
12.2. Mergers & Acquisitions
12.3. Product Launches
13. COMPETITIVE LANDSCAPE
13.1. Business Overview
13.2. Company Snapshot
13.3. Products & Services
13.4. Financials (As reported)
13.5. Recent Developments
13.6. SWOT Analysis
13.6.1. Medtronic Plc.
13.6.2. Boston Scientific Corporation
13.6.3. Abbott Laboratories, Inc.
13.6.4. Terumo Corporation
13.6.5. Johnson & Johnson
13.6.6. Cordis Corporation
13.6.7. ReCor Medical, Inc. (Otsuka Holdings)
13.6.8. Cardiosonic Ltd
13.6.9. Mercator MedSystems, Inc
13.6.10. Renal Dynamics Limited
14. STRATEGIC RECOMMENDATIONS
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. RESEARCH METHODOLOGY
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. EXECUTIVE SUMMARY
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. VOICE OF CUSTOMER
5. GLOBAL RENAL DENERVATION MARKET OUTLOOK
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Technology (Ultrasound Ablation, Radiofrequency Ablation, Pharmacologic Ablation, Microinfusion)
5.2.2. By Product (Catheters, Single Electrode Catheter, Multi Electrode Catheter, RF Generator, Others)
5.2.3. By Therapeutic Area (Hypertension, Heart Failure, Diabetes, Renal Failure, Others)
5.2.4. By End User (Hospitals & Clinics, Ambulatory Care Centers, Others)
5.2.5. By Region
5.2.6. By Company (2022)
5.3. Market Map
5.3.1. By Technology
5.3.2. By Product
5.3.3. By Therapeutic Area
5.3.4. By End User
5.3.5. By Region
6. NORTH AMERICA RENAL DENERVATION MARKET OUTLOOK
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Technology
6.2.2. By Product
6.2.3. By Therapeutic Area
6.2.4. By End User
6.2.5. By Country
6.3. North America: Country Analysis
6.3.1. United States Renal Denervation Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Technology
6.3.1.2.2. By Product
6.3.1.2.3. By Therapeutic Area
6.3.1.2.4. By End User
6.3.2. Mexico Renal Denervation Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Technology
6.3.2.2.2. By Product
6.3.2.2.3. By Therapeutic Area
6.3.2.2.4. By End User
6.3.3. Canada Renal Denervation Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Technology
6.3.3.2.2. By Product
6.3.3.2.3. By Therapeutic Area
6.3.3.2.4. By End User
7. EUROPE RENAL DENERVATION MARKET OUTLOOK
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Technology
7.2.2. By Product
7.2.3. By Therapeutic Area
7.2.4. By End User
7.2.5. By Country
7.3. Europe: Country Analysis
7.3.1. France Renal Denervation Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Technology
7.3.1.2.2. By Product
7.3.1.2.3. By Therapeutic Area
7.3.1.2.4. By End User
7.3.2. Germany Renal Denervation Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Technology
7.3.2.2.2. By Product
7.3.2.2.3. By Therapeutic Area
7.3.2.2.4. By End User
7.3.3. United Kingdom Renal Denervation Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Technology
7.3.3.2.2. By Product
7.3.3.2.3. By Therapeutic Area
7.3.3.2.4. By End User
7.3.4. Italy Renal Denervation Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Technology
7.3.4.2.2. By Product
7.3.4.2.3. By Therapeutic Area
7.3.4.2.4. By End User
7.3.5. Spain Renal Denervation Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Technology
7.3.5.2.2. By Product
7.3.5.2.3. By Therapeutic Area
7.3.5.2.4. By End User
8. ASIA-PACIFIC RENAL DENERVATION MARKET OUTLOOK
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Technology
8.2.2. By Product
8.2.3. By Therapeutic Area
8.2.4. By End User
8.2.5. By Country
8.3. Asia-Pacific: Country Analysis
8.3.1. China Renal Denervation Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Technology
8.3.1.2.2. By Product
8.3.1.2.3. By Therapeutic Area
8.3.1.2.4. By End User
8.3.2. India Renal Denervation Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Technology
8.3.2.2.2. By Product
8.3.2.2.3. By Therapeutic Area
8.3.2.2.4. By End User
8.3.3. Japan Renal Denervation Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Technology
8.3.3.2.2. By Product
8.3.3.2.3. By Therapeutic Area
8.3.3.2.4. By End User
8.3.4. South Korea Renal Denervation Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Technology
8.3.4.2.2. By Product
8.3.4.2.3. By Therapeutic Area
8.3.4.2.4. By End User
8.3.5. Australia Renal Denervation Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Technology
8.3.5.2.2. By Product
8.3.5.2.3. By Therapeutic Area
8.3.5.2.4. By End User
9. SOUTH AMERICA RENAL DENERVATION MARKET OUTLOOK
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Technology
9.2.2. By Product
9.2.3. By Therapeutic Area
9.2.4. By End User
9.2.5. By Country
9.3. South America: Country Analysis
9.3.1. Brazil Renal Denervation Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Technology
9.3.1.2.2. By Product
9.3.1.2.3. By Therapeutic Area
9.3.1.2.4. By End User
9.3.2. Argentina Renal Denervation Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Technology
9.3.2.2.2. By Product
9.3.2.2.3. By Therapeutic Area
9.3.2.2.4. By End User
9.3.3. Colombia Renal Denervation Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Technology
9.3.3.2.2. By Product
9.3.3.2.3. By Therapeutic Area
9.3.3.2.4. By End User
10. MIDDLE EAST AND AFRICA RENAL DENERVATION MARKET OUTLOOK
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Technology
10.2.2. By Product
10.2.3. By Therapeutic Area
10.2.4. By End User
10.2.5. By Country
10.3. MEA: Country Analysis
10.3.1. South Africa Renal Denervation Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Technology
10.3.1.2.2. By Product
10.3.1.2.3. By Therapeutic Area
10.3.1.2.4. By End User
10.3.2. Saudi Arabia Renal Denervation Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Technology
10.3.2.2.2. By Product
10.3.2.2.3. By Therapeutic Area
10.3.2.2.4. By End User
10.3.3. UAE Renal Denervation Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Technology
10.3.3.2.2. By Product
10.3.3.2.3. By Therapeutic Area
10.3.3.2.4. By End User
10.3.4. Egypt Renal Denervation Market Outlook
10.3.4.1. Market Size & Forecast
10.3.4.1.1. By Value
10.3.4.2. Market Share & Forecast
10.3.4.2.1. By Technology
10.3.4.2.2. By Product
10.3.4.2.3. By Therapeutic Area
10.3.4.2.4. By End User
10.3.5. Turkey Renal Denervation Market Outlook
10.3.5.1. Market Size & Forecast
10.3.5.1.1. By Value
10.3.5.2. Market Share & Forecast
10.3.5.2.1. By Technology
10.3.5.2.2. By Product
10.3.5.2.3. By Therapeutic Area
10.3.5.2.4. By End User
11. MARKET DYNAMICS
11.1. Drivers
11.2. Challenges
12. MARKET TRENDS & DEVELOPMENTS
12.1. Recent Developments
12.2. Mergers & Acquisitions
12.3. Product Launches
13. COMPETITIVE LANDSCAPE
13.1. Business Overview
13.2. Company Snapshot
13.3. Products & Services
13.4. Financials (As reported)
13.5. Recent Developments
13.6. SWOT Analysis
13.6.1. Medtronic Plc.
13.6.2. Boston Scientific Corporation
13.6.3. Abbott Laboratories, Inc.
13.6.4. Terumo Corporation
13.6.5. Johnson & Johnson
13.6.6. Cordis Corporation
13.6.7. ReCor Medical, Inc. (Otsuka Holdings)
13.6.8. Cardiosonic Ltd
13.6.9. Mercator MedSystems, Inc
13.6.10. Renal Dynamics Limited
14. STRATEGIC RECOMMENDATIONS
